CeleScreen

📍 Paris, France👥 3 employees💰 Last funded Jan 2015
Personal Care Product Manufacturing🌐 celescreen.com
Website LinkedIn
CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health. Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in CeleScreen?
CeleScreen has 1 investors on record on gritt.io.
When did CeleScreen last raise funding?
The most recent investment in CeleScreen recorded on gritt.io was in January 2015.
What industry is CeleScreen in?
CeleScreen operates in Personal Care Product Manufacturing. Find similar Personal Care Product Manufacturing investors on gritt.io.
Where is CeleScreen based?
CeleScreen is headquartered in Paris, France.